These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 25963687)

  • 1. [Second-line chemotherapy for advanced pancreatic cancer].
    Sato A; Saito K; Takahata T
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):403-7. PubMed ID: 25963687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
    Zaniboni A; Aitini E; Barni S; Ferrari D; Cascinu S; Catalano V; Valmadre G; Ferrara D; Veltri E; Codignola C; Labianca R
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1641-5. PubMed ID: 22576338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Li J; Merl MY; Saif MW
    JOP; 2010 Mar; 11(2):151-3. PubMed ID: 20208325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of post-operative recurrence of pancreatic cancer in the residual pancreas treated by resection of the residual pancreas following radiological complete response achieved with second-line FOLFIRINOX].
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Mori R; Matsuyama R; Taniguchi K; Tanaka K; Akiyama H; Endo I; Ichikawa Y
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):901-4. PubMed ID: 25131881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Brus C; Saif MW
    JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
    Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
    Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status in chemotherapy for advanced pancreatic adenocarcinoma.
    Cao H; LE D; Yang LX
    Anticancer Res; 2013 May; 33(5):1785-91. PubMed ID: 23645722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
    Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results.
    Teo M; McDermott RS
    Ann Oncol; 2013 Sep; 24(9):2462-3. PubMed ID: 23986547
    [No Abstract]   [Full Text] [Related]  

  • 16. FOLFIRINOX: desert, oasis, or mirage?
    Ferrone CR
    Ann Surg Oncol; 2015 Apr; 22(4):1059-60. PubMed ID: 25490873
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytotoxic Chemotherapy in Advanced Pancreatic Cancer.
    Rehman M; Khaled A; Noel M
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1011-1018. PubMed ID: 36154782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W
    Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Okusaka T; Ikeda M; Fukutomi A; Ioka T; Furuse J; Ohkawa S; Isayama H; Boku N
    Cancer Sci; 2015 Aug; 106(8):1101-2. PubMed ID: 26268894
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy in pancreatic cancer: a rational pursuit?
    Wils JA
    Anticancer Drugs; 1991 Feb; 2(1):3-10. PubMed ID: 1958849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.